1. Home
  2. Category
  3. Diagnosis and Screening

Treatment Decision Making

Article

Initial Efficacy Testing of an Autobiographical Memory Intervention on Advance Care Planning for Patients With Terminal Cancer

Cheryl Brohard
ONF 2017, 44(6), 751-763 DOI: 10.1188/17.ONF.751-763
Purpose/Objectives: To test the efficacy of a novel intervention to facilitate advance care planning. Design: Exploratory, quasiexperimental pilot study with two independent groups. Setting: A large hospice located in the southwestern United States. Sample: A convenience sample of 50 participants...
0
No votes yet
Read this Article
Article

Venetoclax: Management and Care for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Heather Brumbaugh Paradis
Debbie Alter
Diane Llerandi
CJON 2017, 21(5), 604-610 DOI: 10.1188/17.CJON.604-610
Background: Venetoclax (Venclexta™) is a potent, selective, orally available, small-molecule B-cell lymphoma 2 inhibitor that achieves response rates of about 80% and has an acceptable safety profile for patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Objectives: The aim...
0
No votes yet
Read this Article
CNE Article

PD-1 Inhibitor Therapy: Consensus Statement From the Faculty of the Melanoma Nursing Initiative on Managing Adverse Events

Suzanne McGettigan
Krista M. Rubin
CJON 2017, 21(4), 42-51 DOI: 10.1188/17.CJON.S4.42-51
Background: Programmed cell death protein 1 (PD-1) inhibitor therapies are now a standard treatment for advanced melanoma and other tumor types. The immune-related adverse events (irAEs) associated with PD-1 inhibitor therapy are drastically different from the AEs associated with chemotherapy...
0
No votes yet
Read this Article
CNE Article

Intralesional Therapy: Consensus Statements for Best Practices in Administration From the Melanoma Nursing Initiative

Virginia Seery
CJON 2017, 21(4), 76-86 DOI: 10.1188/17.CJON.S4.76-86
Background: Talimogene laherparepvec (T-VEC) is the first intralesional therapy for melanoma approved by the U.S. Food and Drug Administration. This oncolytic viral immunotherapy has improved outcomes for patients with locoregional recurrent melanoma and is showing promise in combination with...
0
No votes yet
Read this Article
Supportive Care

Scalp Cooling: The Prevention of Chemotherapy-Induced Alopecia

Anne Katz
CJON 2017, 21(4), 413-415 DOI: 10.1188/17.CJON.413-415
Hair loss (alopecia) from chemotherapy is one of the most feared side effects of many patients, particularly women. Many patients and their healthcare providers believe that cryotherapy can help prevent or mitigate these changes. Scalp cooling has been used for more than 30 years to prevent...
0
No votes yet
Read this Article

Questions, Concerns or Requests

We're just a click away for assistance.